L
Lucia Masarova
Researcher at University of Texas MD Anderson Cancer Center
Publications - 134
Citations - 1814
Lucia Masarova is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 16, co-authored 84 publications receiving 749 citations. Previous affiliations of Lucia Masarova include University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
Courtney D. DiNardo,Abhishek Maiti,Caitlin R. Rausch,Naveen Pemmaraju,Kiran Naqvi,Naval Daver,Tapan M. Kadia,Gautam Borthakur,Maro Ohanian,Yesid Alvarado,Ghayas C. Issa,Guillermo Montalban-Bravo,Nicholas J. Short,Musa Yilmaz,Prithviraj Bose,Elias Jabbour,Koichi Takahashi,Jan A. Burger,Guillermo Garcia-Manero,Nitin Jain,Steven M. Kornblau,Philip A. Thompson,Zeev Estrov,Lucia Masarova,Koji Sasaki,Srdan Verstovsek,Alessandra Ferrajoli,William Weirda,Sa A. Wang,Sergej Konoplev,Zhining Chen,Sherry Pierce,Jing Ning,Wei Qiao,Farhad Ravandi,Michael Andreeff,John S. Welch,Hagop M. Kantarjian,Marina Konopleva +38 more
TL;DR: It is hypothesized that venetoclax with 10-day decitabine could have improved activity in patients with newly diagnosed AML and those with relapsed or refractory AML, particularly in high-risk subgroups, as well as safety, overall survival, and duration of response.
Journal ArticleDOI
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Courtney D. DiNardo,Curtis Lachowiez,Koichi Takahashi,Sanam Loghavi,Lianchun Xiao,Tapan M. Kadia,Naval Daver,Maria Adeoti,Nicholas J. Short,Koji Sasaki,Sa Wang,Gautam Borthakur,Ghayas C. Issa,Abhishek Maiti,Yesid Alvarado,Naveen Pemmaraju,Guillermo Montalban Bravo,Lucia Masarova,Musa Yilmaz,Nitin Jain,Michael Andreeff,Elias Jabbour,Guillermo Garcia-Manero,Steven M. Kornblau,Farhad Ravandi,Marina Konopleva,Hagop M. Kantarjian +26 more
TL;DR: The authors showed that 60% of newly diagnosed patients with acute myeloid leukemia (ND-AML) receiving frontline therapy attain complete response (CR) yet 30%-40% of patients relapse.
Journal ArticleDOI
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
Lucia Masarova,Srdan Verstovsek,Juliana E. Hidalgo-Lopez,Naveen Pemmaraju,Prithviraj Bose,Zeev Estrov,Elias Jabbour,Farhad Ravandi-Kashani,Koichi Takahashi,Jorge E. Cortes,Jing Ning,Maro Ohanian,Yesid Alvarado,Lingsha Zhou,Sherry Pierce,Romany Gergis,Keyur P. Patel,Rajyalakshmi Luthra,Tapan M. Kadia,Courtney D. DiNardo,Gautam Borthakur,Kapil N. Bhalla,Guillermo Garcia-Manero,Carlos E. Bueso-Ramos,Hagop M. Kantarjian,Naval Daver +25 more
TL;DR: Ruxolitinib (RUX)-based combinations may provide benefit for patients with myelofibrosis and AZA were safe, with encouraging spleen response rates and improvement in bone marrow fibrosis in patients with MF.
Journal ArticleDOI
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.
Warren Fiskus,Tianyu Cai,Courtney D. DiNardo,Steven M. Kornblau,Gautam Borthakur,Tapan M. Kadia,Naveen Pemmaraju,Prithviraj Bose,Lucia Masarova,Kimal Rajapakshe,Dimuthu Perera,Cristian Coarfa,Christopher P. Mill,Dyana T. Saenz,David N. Saenz,Baohua Sun,Joseph D. Khoury,Yu Shen,Marina Konopleva,Kapil N. Bhalla +19 more
TL;DR: Compared to treatment with either agent alone, cotreatment with ABBV-075 and venetoclax was significantly more effective in reducing AML cell-burden and improving survival, without inducing toxicity, in AML-engrafted immune-depleted mice.
Journal ArticleDOI
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Abhishek Maiti,Wei Qiao,Koji Sasaki,Farhad Ravandi,Tapan M. Kadia,Elias Jabbour,Naval Daver,Gautam Borthakur,Guillermo Garcia-Manero,Sherry Pierce,Kathryn S. Montalbano,Naveen Pemmaraju,Kiran Naqvi,Maro Ohanian,Nicholas J. Short,Yesid Alvarado,Koichi Takahashi,Musa Yilmaz,Nitin Jain,Steven M. Kornblau,Michael Andreeff,Prithviraj Bose,Alessandra Ferrajoli,Ghayas C. Issa,Lucia Masarova,Philip A. Thompson,Caitlin R. Rausch,Jing Ning,Hagop M. Kantarjian,Courtney D. DiNardo,Marina Konopleva +30 more
TL;DR: In patients at both at high‐risk and low‐risk of TRM, DEC10‐VEN showed significantly higher CR/CRi, lower 30‐day mortality, and longer overall survival compared to IC.